D. Ross Camidge

D. Ross Camidge at the University of Colorado has been central to the clinical development of ALK inhibitors including crizotinib, alectinib, and next-generation ALK inhibitors for ALK-rearranged NSCLC. He contributed to the PROFILE clinical trials that established crizotinib and contributed to the development of brigatinib and lorlatinib. His research on ALK inhibitor resistance mechanisms and optimal treatment sequencing has helped define treatment algorithms for ALK-positive lung cancer. His comprehensive clinical research spanning ALK, ROS1, and other oncogenic fusions in lung cancer has advanced precision oncology for this disease.